Mitra Hashemi, MD
Geriatric Medicine · Silver Spring, MDNPI 1225354905
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,549 of the $4,749 with a category attached, or 74.7%. 33 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 26.2% of the total. Reporting peaked in 2021 at $1,792 and has fallen 51.9% since, to $861 in 2025.
Across 171 payments — averaging $27.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- Novo Nordisk$485
- Lilly USA, LLC$430
- AstraZeneca$367
- Exact Sciences$278
- Pfizer$252
- plus $2K from 27 others
What the payments were for
- Consulting fees$1,20025%
- Food & beverage$3,54975%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 4 | $1,246 |
| Novo Nordisk | 25 | $485 |
| Lilly USA, LLC | 23 | $430 |
| AstraZeneca | 17 | $367 |
| Exact Sciences | 13 | $278 |
| Pfizer | 14 | $252 |
| Amgen | 13 | $244 |
| Boehringer Ingelheim | 7 | $186 |
| Esperion Therapeutics, Inc. | 2 | $139 |
| AbbVie | 6 | $121 |
| Astellas Pharma US Inc | 6 | $101 |
| Johnson & Johnson | 2 | $98 |
| GSK | 4 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $70 |
| Abbott | 3 | $66 |
| Merck | 4 | $65 |
| Nevro Corp. | 1 | $61 |
| Amarin Pharma, Inc. | 3 | $58 |
| Biogen | 3 | $53 |
| Seqirus USA Inc | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Bayer | 2 | $35 |
| Lundbeck LLC | 1 | $29 |
| Sanofi Pasteur Inc. | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $25 |
| BD | 1 | $25 |
| Boston Scientific | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $21 |
| Lifescan, Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Grifols USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- NEXLIZET$124
- NEXLETOL$124
How this compares
$4,749 in reported general payments places this provider in the 85th percentile of 112 geriatric medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $57,487 |
| JardianceEmpagliflozin | 45 | $56,540 |
| MounjaroTirzepatide | 39 | $50,846 |
| FarxigaDapagliflozin Propanediol | 31 | $32,540 |
| Atorvastatin Calcium | 306 | $3,055 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,889 |
| SynthroidLevothyroxine Sodium | 19 | $2,073 |
| Rosuvastatin Calcium | 90 | $2,001 |
| Solifenacin Succinate | 12 | $1,631 |
| Duloxetine Hcl | 24 | $1,540 |
| Levothyroxine Sodium | 135 | $1,428 |
| Metoprolol Succinate | 72 | $1,240 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 17 | $1,078 |
| Propranolol Hcl ErPropranolol Hcl | 12 | $1,033 |
| Amlodipine Besylate | 142 | $1,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $485 | $57,48749 claims |
| Boehringer IngelheimJardiance | $186 | $56,54045 claims |
| Lilly USA, LLCMounjaro | $430 | $50,84639 claims |
| AstraZenecaFarxiga | $367 | $32,54031 claims |
| GSKArnuity Ellipta | $80 | $2,88913 claims |
| AbbVieSynthroid | $121 | $2,07319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 112 geriatric medicine providers in Maryland.
Other geriatric medicine in Silver Spring
- Shyamsundar RajanSilver Spring$2K
- Xiao Chun YangSilver Spring$2K
- Ruth Kevess-CohenSilver Spring$167
- Sean LengBaltimore$412K
- Jocelyn El-SayedBaltimore$84K
- Joanne LynnChevy Chase$52K
- James LettRockville$33K
- Marcelino AlbuerneCatonsville$14K
- Lee MusherChevy Chase$13K
- Raman TuliGaithersburg$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.